Compare TC Energy Corporation Common Stock (TRP) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TC Energy Corporation Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? TC Energy Corporation Common Stock trades at $61.12 (market cap $63.97B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: TC Energy Corporation Common Stock is far larger — about 13.1× Travere Therapeutics Inc. Common Stock's market cap, and TC Energy Corporation Common Stock pays a 4.02% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TC Energy Corporation Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TRP | TVTX | |
|---|---|---|
Market Cap | $63.97B | $4.88B |
Volume | 3,039,280 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $70.91 | $67.52 |
52-Week Low | $49.79 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $108.73B | $5.01B |
Dividend Yield | 4.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRP trades at $61.55, up 1.63% with a bullish technical signal despite mixed moving averages. The company shows solid fundamentals with $15.24B revenue, 22.91% net margin, and consistent EBITDA growth. Recent developments include Coastal GasLink Phase 2 expansion approval and a $400M pipeline divestiture, positioning for long-term natural gas demand growth. Analyst consensus is strongly bullish with a $85 price target representing 38% upside potential.
TRP presents a compelling investment case with strong profitability, strategic growth initiatives, and overwhelming analyst support. Key risks include execution challenges on major projects, interest rate sensitivity, and energy market volatility. The stock's current valuation at 25x P/E appears reasonable given growth prospects and 4.3% dividend yield, though technical indicators suggest near-term consolidation may occur.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TC Energy Corporation Common Stock
TC Energy operates energy infrastructure, including natural gas pipelines and storage systems. Its assets transport energy across North America.
Read more on TRP →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
